Adjunctive Immunotherapeutic efficacy of an N-formylated internal peptide of mycobacterial glutamine synthetase in mouse model of tuberculosis.
Host-directed therapies are a relatively new and promising approach for the treatment of tuberculosis. A range of host pathways, vaccines and drugs have the potential to provide new adjunctive therapies for tuberculosis. In this connection, we have earlier reported the immunotherapeutic potential of N-formylated N-terminal peptide of glutamine synthetase of Mycobacterim tuberculosis H37Rv (Mir SA and Sharma S, 2014). Now in the present study, we investigated the immunotherapeutic effect of N-terminally formylated internal peptide 'f-MLLLPD' of mycobacterial glutamine synthetase (Rv2220) in mouse model of tuberculosis. The N-terminally formylated peptide, f-MLLLPD was tested for its potential to generate reactive oxygen species (ROS) in murine neutrophils. Further, its therapeutic effect alone or in combination with anti-tubercular drugs was evaluated in mouse model of tuberculosis. The N-formylated peptide (f-MLLLPD) treatment alone and in combination with ATDs reduced the colony forming units (CFU) in lungs of infected mice by 0.58 (p<0.01) and 2.92 (p<0.001) log10 units respectively and in their spleens by 0.46 (p<0.05) and 2.46 (p<0.001) log10 units respectively. The histopathological changes in the lungs of infected mice also correlated well with the CFU data. Our results clearly indicate that f-MLLLPD peptide conferred an additional therapeutic effect when given in combination with the anti-tuberculosis drugs.